Arcadia Biosciences, Inc. (RKDA) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
RKDA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Arcadia Biosciences, Inc. (RKDA) trades at a price-to-earnings ratio of -0.6x, with a stock price of $1.10 and trailing twelve-month earnings per share of $-1.71.
The current P/E is 107% below its 5-year average of 9.3x. Over the past five years, RKDA's P/E has ranged from a low of 9.3x to a high of 9.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Basic Materials sector median P/E of 23.4x, RKDA trades at a 103% discount to its sector peers. The sector includes 125 companies with P/E ratios ranging from 2.0x to 144.2x.
Relative to the broader market, RKDA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our RKDA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
RKDA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $53B | 49.4 | 4.14Best | +23%Best | |
| $37B | 34.8 | - | -39% | |
| $24B | 25.2Lowest | - | -38% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
RKDA Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $2.97 | $0.32 | 9.3x | +0% |
Average P/E for displayed period: 9.3x
See RKDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs RKDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare RKDA vs LIN
Side-by-side business, growth, and profitability comparison vs Linde plc.
Start ComparisonRKDA — Frequently Asked Questions
Quick answers to the most common questions about buying RKDA stock.
Is RKDA stock overvalued or undervalued?
RKDA trades at -0.6x P/E, below its 5-year average of 9.3x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does RKDA's valuation compare to peers?
Arcadia Biosciences, Inc. P/E of -0.6x compares to sector median of 23.4x. The discount suggests lower growth expectations or higher risk.
What is RKDA's PEG ratio?
RKDA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.